{"organizations": [], "uuid": "8e0a47328a9d9e61b1b2b387cc1e68b639d6ab52", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-reata-announces-improvements-in-ki/brief-reata-announces-improvements-in-kidney-function-with-bardoxolone-methyl-maintained-for-two-years-in-pah-patients-from-lariat-trial-idUSFWN1Q21GW", "country": "US", "domain_rank": 408, "title": "BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.159, "site_type": "news", "published": "2018-02-13T05:42:00.000+02:00", "replies_count": 0, "uuid": "8e0a47328a9d9e61b1b2b387cc1e68b639d6ab52"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-reata-announces-improvements-in-ki/brief-reata-announces-improvements-in-kidney-function-with-bardoxolone-methyl-maintained-for-two-years-in-pah-patients-from-lariat-trial-idUSFWN1Q21GW", "ord_in_thread": 0, "title": "BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "reata pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Reata Pharmaceuticals Inc:\n* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T05:42:00.000+02:00", "crawled": "2018-02-13T16:00:35.009+02:00", "highlightTitle": ""}